Semaglutide use before single-level lumbar fusion associated with fewer readmissions and 90-day costs.

Although secondary surgical outcomes did not significantly differ between the semaglutide and control cohorts, incidences of SSI exhibited a decreasing trend among semaglutide patients following single-level lumbar fusion.

also in 47,180 other papers

CONCLUSIONS The use of semaglutide at the time of single-level lumbar fusion was associated with a significantly decreased risk of readmission within 90 days of surgery and a lower incidence of SSI, although this difference did not reach statistical significance.

also in 111,027 other papers

Further, in accordance with the aforementioned studies, the current study also points to a lower average same-day reimbursement and average LOS postoperatively, although this difference failed to reach significance.[ 12 , 13 ] Since this study used a national patient database, several potential limitations exist.

also in 4,113 other papers

Furthermore, the findings point to a lower average same-day reimbursement, although this difference failed to reach statistical significance.

also in 6,035 other papers